6CM
AMLX icon

683 Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

683 Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
+96,600
New +$1.36M 0.07% 128

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

683 Capital Management's AMLX Position: Q1 2026 in Review

683 Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 7.3% in Q1 2026, selling an estimated $1.69M and leaving 1,530,000 shares worth $21.3M. The position accounts for 1.11% of the portfolio, ranked #19.

683 Capital Management first reported a position in AMLX in Q1 2022 and has held it in 10 quarters since. The position peaked at $23.9M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • 683 Capital Management held 1,530,000 shares of Amylyx Pharmaceuticals worth $21.3M as of Q1 2026.
  • 683 Capital Management sold 120,000 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.69M.
  • Amylyx Pharmaceuticals made up 1.11% of 683 Capital Management's portfolio in Q1 2026, its #19 holding.
  • 683 Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • 683 Capital Management's Amylyx Pharmaceuticals position peaked at $23.9M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.